The company's HCCscreen assay will be used in a liver cancer screening public health initiative, generating real-world data on the test's clinical validity and impact.
Dubbed Automobi Molecular Diagnostics, the company will establish local manufacturing facilities and work to commercialize the Novodiag platform in China.
Through the JV and strategic partnership, the companies aim to provide precision diagnostic products and services to Hong Kong, Macau, South Korea, and Southeast Asia.